Nevakar spins off ophthalmic-only company Vyluma

Video

A new ophthalmic-only pharma company was formed when Nevakar spun off its pipeline of ocular drugs.

Navneet Puri, PhD, founder, chairman, and CEO of newly formed Vyluma discusses why Nevakar chose to make the move to ophthalmic-only pharma.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Paul Karpecki, OD, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
© 2025 MJH Life Sciences

All rights reserved.